This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryAdditional orphan indication for somatropin clears FDA July 25 for long-term treatment of growth failure in children who were born small for gestational age and who do not achieve catch-up growth by age two
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of PFS targets in the pancreatic setting.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.